996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Basic Info

  • Grade: Pharmaceutical Grade

    Factory Location: Quanzhou

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Payment Terms: L/C

    Apalutamide is a second-generation highly selective androgen receptor antagonist, and its affinity with androgen receptors is more than 5 times that of the first-generation androgen receptor antagonists. A phase III study involving 1207 patients with non-metastatic castration-resistant prostate cancer demonstrated that apalutamide significantly prolonged metastasis-free survival (40.5 vs 16.2 months) compared with placebo. 2018/2/14, Apalutamide was approved by the FDA for the treatment of non-metastatic (prostate cancer cells have not spread) castration-resistant prostate cancer (the disease still progresses after hormone therapy)

Send your message to this supplier
  • From:
  • To:
    Quanzhou Fortune Biopharma Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    -?Supports?jpg,?jpeg,?png,
    ?gif,?pdf,?doc,?docx,
    ?xls,?xlsx,?txt,?rar?and?zip
    -?Max?upload?3?files;
    ?Max??total?size:?3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service